These data suggest that the inhibition of PLK-1 results in convincing anti-leukemic effects by the reduction in viability, induction of cell cycle arrest, and, finally, apoptosis in infant MLL fusion protein-driven leukemia with significantly less impact on both adult MLLr leukemia and control cells. The gene discussed is PLK1; the disease is leukemia.